Overview

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

Status:
Completed

Trial end date:
2017-09-03

Target enrollment:

Participant gender:

Summary

This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Liraglutide